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Background: Many different pouch failure (PF) indications and pro-
cedures are known. In literature, different types of PF are randomly 
classified and often stacked together due to complexity. Transanal 
minimally invasive surgery (TAMIS) is becoming increasingly popular 
for redo-surgery due to greater accessibility and visibility in complex 
pelvic surgery compared with the conventional abdominal approach. 
We aimed to evaluate the efficacy of TAMIS in patients with PF.
Methods: This retrospective study includes all consecutive patients 
over 18-year old with an ileal pouch-anal anastomosis (IPAA) and 
PF that were managed with TAMIS between July 2014 and July 
2019. Patient characteristics, operative indications, perioperative 
outcomes and short-term follow-up (FU) are described using a sug-
gested subclassification for surgical-related PF (Figure 1).
Results: Forty-six procedures were completed in 42 patients, predom-
inantly male (66.7%) with a median age of 44.6 (range 22.0–70.8) 
years. Initial IPAA indications were familial adenomatous polyposis 
(n = 11), medical refractory ulcerative colitis (UC) (n = 29) or other (n 
= 2). Seven (24.1%) UC patients turned out to have Crohn’s disease 
(CD). Reasons for PF were septic complications (n = 18), retained 
rectum (n = 3), outlet problems (n = 8)  (with megapouch: n = 5), 
inlet problems (n = 6), cuff problems (n = 8) and refractory pouchi-
tis with unknown aetiology (n = 3). Twenty-three pouch redo’s (16 
remodelling, 7 new pouches), 5 sleeve advancements, 4 cuff excisions, 
1 posterior pouchpexy, and 13 pouch excisions were recorded. Five 
pouch excisions were performed in CD patients. Five procedures 
were fully completed transanally, and 41 were a combined transab-
dominal (with 32 open and 9 laparoscopic) and TAMIS approach. 
None were converted to an open procedure. Apart from the patients 
with a pouch excision, 9 ended up with a permanent ileostomy, al-
though technical success was achieved in 4 of those. Six permanent 
ileostomies were in patients with a redo-pouch (3 remodelling, 3 new 
pouches), 2 after sleeve advancement and 1 after cuff excision. Major 
morbidity (Clavien-Dindo ≥3) occurred after 17 procedures (37.0%), 
14 within 1 month after surgery with a median FU of 17.9 (0.9–41.6) 
months. There was no peri-operative mortality.
Conclusion: TAMIS for PF after IPAA is technically feasible with 
acceptable short-term outcomes. Peri-operative morbidity is high 
and reflects the complexity of these procedures. Success after PF 
procedures is difficult to interpret due to a wide range of pos-
sible outcomes such as technical success, conversion rate and 
number of patients with a permanent stoma. The PF subclassifica-
tion makes the complex problem and surgical management of PF 
comprehensible.
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Background: Proteomic biomarkers have been linked to anti-TNF 
treatment failure, but previous studies have been insufficiently pow-
ered to stratify associations by drug level. The Personalised Anti-TNF 
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Therapy in Crohn’s disease (PANTS) is a prospective UK-wide study 
investigating treatment failure in 1610 anti-TNF naïve patients. We 
aimed to identify proteomic markers of treatment failure.
Methods: We sampled patients with primary non-response (PNR) 
(n = 223) and remission (n = 219) who had a baseline CRP ≥4 mg/l 
and/or calprotectin >100 µg/g. PNR was defined at week 14 as on-
going steroids, or both of HBI failed to fall by ≥3 points or to ≤4 and 
CRP failed to fall by ≥50% or to ≤3 mg/l. Non-remission at week 54 
was defined as HBI >4 and CRP >3 mg/l and no steroids. Targeted 
serum proteomic analysis of 180 proteins using Olink Inflammation 
and Immune Response panels were performed. Mann–Whitney U 
tests were used to identify baseline proteins that predicted PNR 
and non-remission. Sub-group analyses stratified by drug level were 
undertaken. Pharmacokinetic (PK) failure was defined as PNR with 
low drug level (infliximab level <2 mg/l, adalimumab level <6 mg/l) 
and pharmacodynamic (PD) failure as PNR despite adequate drug 
level. Significant proteins were entered into multivariable logistic 
regression models and Bayesian information criterion (BIC) with 
backward stepwise selection were used to build predictive models 
of treatment failure. We applied 10-fold cross-validation to test the 
models. P-values of < 0.05 were considered significant.
Results: Elevated fibroblast growth factor 21 (FGF21) (OR 1.3, CI 
1.1–1.4, p = 3.4 × 10–5) and interleukin-10 receptor subunit α (IL10RA) 
(OR 1.6, CI 1.2–2.1, p = 6.3 × 10–4) predicted PNR (Figure 1). At week 
14, FGF21 (OR 1.5, CI 1.3–1.9, p = 1.8 × 10–6) and IL10RA (OR 1.8, 
CI 1.3–2.3, p = 5.8 × 10–5) levels were also associated with PNR.
Sub-group analyses showed baseline FGF21 (OR 1.4, CI 1.2–1.7, 
p = 2.0 × 10–4) predicted PK failure and that IL10-RA (OR 1.6, CI 
1.1–2.2, p = 6.7 × 10–3) predicted PD failure (Figure 2).
In separate models, non-remission at week 54 was predicted by 
baseline (FGF21; OR 1.3, CI 1.1–1.4, p  =  1.4 × 10–4, IL10-RA; 
OR 1.5, CI 1.1–2.0, p  =  3.6  × 10–3) and week 14 (FGF21; OR 
1.4, CI 1.2–1.7, p  =  3.6  × 10–4, IL10-RA; OR 1.7, CI 1.3–2.4, 
p = 1.7 × 10–4) FGF21 and IL10-RA levels. Model validation of 
baseline FGF21 and IL10-RA showed an area under the curve of 
0.61 (CI 0.57–0.64) for PNR and 0.60 (CI 0.56–0.64) for non-
remission at week 54.
Conclusion: Our study identified FGF-21 and IL10-RA as proteins 
of interest associated with PK and PD treatment failure, respectively. 
Functional studies to determine the molecular mechanism driving 
dysregulation of these proteins are required.
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Background: CD is defined by transmural inflammation lead-
ing to inflammatory, stricturing and/or penetrating phenotypes. 
Identifying underlying molecular pathways and distinct disease 
subsets is critical for improved prognostics, therapeutics and bio-
marker discovery.
Methods: CD3+ T cells were purified from paired blood and mu-
cosal tissue from 101 CD and 17 non-IBD subjects requiring surgery. 
Longitudinal samples (n = 30) were collected 4–13 mo. post-surgery. 
Expression profiles were generated by RNAseq, T-cell subset de-
convolution by xCell and transcriptome-wide associations (TWAS) 
using TWAS-hub.
Results: Unsupervised clustering of peripheral T-cell gene expres-
sion at surgery revealed 2 CD profiles: Expression from cluster1, 
labelled CD-PBT (63%), clustered tightly with the non-IBD 
group. In cluster2, expression shifted from a peripheral toward a 
mucosal profile, labelled CD-PBmu(cosal) (37%). CD-PBmu was 
defined by differentially expressed genes (DEG) (1944 DEG, p 
< 0.001) regulating cell migration and adhesion pathways and 
a distinct T-cell subset composition associated with stricturing 
disease (p = 0.03), increased resected bowel length (p = 0.036) 
and post-op recurrence (p = 0.01). There were no significant dif-
ferences in disease location/behaviour. Independent validation 
(5 public datasets) confirmed the CD-PBmu signature in data 
from whole blood (CD patients failing anti-TNF therapy, n = 
204)  and the mucosal-like expression profile in data from ileal 
tissue (paediatric CD patients, studies n = 751). A defining feature 
of CD-PBmu, validated in a separate CD cohort (n = 19), was 
decreased pro-inflammatory cytokine/chemokine and adhesion 
molecule expression following surgery (900 DEG, p < 0.001). 
No post-surgery change in expression was detected in CD-PBT. 
A 44-gene classifier was identified to enable clinical application. 
The classifier accurately detected the CD-PBmu patient subtype, 
correlated with the altered composition of peripheral T-cell sub-
sets and overlapped with IBD associated TWAS signals (>60%). 
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